Thrombophilias in ob/gyn: Part II: Treatment strategies

Emergency Medicine

Volumn 47, Issue 11, 2002, Pages 59-70

  Katz, Vern L ^a  

^a Sacred Heart Medical Center Eugene   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346108542     PISSN: 00136654     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Meschia JF, Biller J, Witt T, et al. Is hormone replacement a risk factor for ischemic stroke in women with factor V Leiden mutation? Arch Neurol. 1998;55: 1137-1139.
2. Vandenbroucke JP, Koster T, Brest E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;334:1453-1457.
3. Van Baal WM, Smolders RG, Van Der Mooren MJ, et al. Hormone replacement therapy and plasma homocysteine levels. Obstet Gynecol. 1999;94:485-491.
4. Ridker PM, Glynn RJ, Miletich JP, et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997;126:528-531.
5. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med. 1999;340:9-13.
6. Lockwood CJ. Inherited thrombophilias in pregnancy patients: detection and treatment paradigm. Obstet Gynecol. 2002;99:333-341.
7. Martinelli I, Taioli E, Cetin I, et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med. 2002;343:1015-1018.
8. Brenner B. Inherited Thrombophilia and Pregnancy Loss. Thromb Haemost. 1999;82:634-640.
9. Walker ID. Thrombophilia in pregnancy. J Clin Pathol. 2000;53:573-580.
10. Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med. 2000;342:374-380.
11. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med. 2001;344:1222-1231.
12. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost. 1997;7:39-43.
13. Brenner B, Hoffman R, Blumenfeld Z, et al. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. Thromb Haemost. 2000;83:693-697.
14. Lepercq J, Conard J, Borel-Derlon A, et al. Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. Br J Obstet Gynaecol. 2001;08:1134-1140.
15. Thromboembolism in Pregnancy. ACOG Practice Bulletin. Number 19, August 2000.
16. Ochshorn V, Kupferminc MJ, Eldor A, et al. Secondtrimester maternal serum alpha-fetoprotein (MSAFP) is elevated in women with adverse pregnancy outcome associated with inherited thrombophilias. Prenat Diagn. 2001;21:658-661.
17. Casele HL, Laifer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol. 1999;181:1113-1117.
18. Gibson JL, Ekevall K, Walker I, et al. Puerperal thromboprophylaxis: comparison of the anti-XA activity of enoxaparin and unfractionated heparin. Br J Obstet Gynaecol. 1998;105:795-797.
19. Anticoagulation with Low-Molecular-Weight Heparin During Pregnancy. ACOG Committee Opinion. Number 211 , November 1998.
20. Brill-Edwards P, Ginsberg JS, Gent M, et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med. 2000;343:1439-1444.